Abstract
Despite thorough investigation, amyotrophic lateral sclerosis (ALS) continues to be adegenerative neurological condition that is inevitably fatal and progresses over time. The limitedunderstanding of the fundamental causes of ALS has posed challenges in addressing the initialbiological processes of the disease, resulting in therapeutic interventions typically being appliedat later stages of the illness.The existence of genetic variants in ALS presents a distinctive chance for advancing therapeuticapproaches, as studying genetic associations could unveil valuable information about the causesof the disease. In the case of genetic ALS, there is a possibility to explore early intervention byidentifying individuals who are at risk and have not yet shown symptoms but possess specificgenetic variations that contribute to the condition. Tofersen, an oligonucleotide, has beenspecifically created to diminish the production of superoxide dismutase 1 (SOD1) protein bybreaking down SOD1 mRNA.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
